Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M683Revenue $M14.2Net Margin (%)-810.9Z-Score9.4
Enterprise Value $M453EPS $-3.3Operating Margin %-986.7F-Score2
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-810.9Higher ROA y-yY
Price/Book2.310-y EBITDA Growth Rate %-9.1Quick Ratio11.9Cash flow > EarningsN
Price/Sales51.65-y EBITDA Growth Rate %25.2Current Ratio11.9Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-32.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-38.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M40.9ROI % (ttm)-300.9Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
($22.49)
$ 16.52-26%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
($31.64)
$ 16.52-48%Add 2620%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 16.52-35%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 16.52-44%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 16.52-57%Add 56.28%665,274
SRPTAndreas Halvorsen 2013-09-30 Sold Out -0.14%$30.906 - $47.97
($38.37)
$ 16.52-57%Sold Out0
SRPTAndreas Halvorsen 2013-03-31 Buy 0.15%$23.97 - $36.95
($28.83)
$ 16.52-43%New holding, 690731 sh.690,731
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 16.52-43%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 16.52-38%Add 184.13%226,429
SRPTJean-Marie Eveillard 2012-03-31 Sold Out $4.5 - $9.6
($6.06)
$ 16.52173%Sold Out0
SRPTJean-Marie Eveillard 2011-12-31 Reduce$3.24 - $6.54
($5.04)
$ 16.52228%Reduce -83.33%50,000
SRPTJean-Marie Eveillard 2011-09-30 Add$6.3 - $9.9
($7.92)
$ 16.52109%Add 50%300,000
SRPTJean-Marie Eveillard 2011-06-30 Buy $8.1 - $11.22
($9.66)
$ 16.5271%New holding, 200000 sh.200,000
SRPTGeorge Soros 2006-03-31 Buy 0.08%$24.54 - $50.45
($41.39)
$ 16.52-60%New holding, 308100 sh.308,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SRPT George Soros 2014-09-30325,0000.790.05-52.21%
Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.9518.42view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.5631.53view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-55.4view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-52.76view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-49.45view
Mahatme SandeshSenior Vice President, CFO 2013-08-20Buy5,000$31.1-46.88view
Price Ben GilDirector 2013-08-19Buy500$31.18-47.02view
CHASE ANTHONY RDirector 2013-06-14Buy10,000$38.5-57.09view
CHASE ANTHONY RDirector 2012-11-28Sell10,000$29.46-43.92view
CHASE ANTHONY RDirector 2012-11-14Sell10,000$25.7-35.72view

Press Releases about SRPT :

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Feb 16 2013 

More From Other Websites
It was another slow, low volume, lackluster trading session Nov 24 2014
Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy... Nov 24 2014
BioMarin's Prosensa Buy: A 'Courageous' Acquisition? Nov 24 2014
BioMarin Buys Prosensa Backs Up Troubled Drug Nov 24 2014
Stock Futures Trending Higher; Kate Spade Bags An Upgrade Nov 24 2014
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Nov 24 2014
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Nov 24 2014
6:25 am Sarepta Therapeutics: Prosensa Holding (RNA) being bought... Nov 24 2014
Sarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant... Nov 21 2014
Robbins Arroyo LLP Is Investigating the Officers and Directors of Sarepta Therapeutics, Inc. (SRPT)... Nov 18 2014
Sarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant... Nov 18 2014
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000... Nov 14 2014
SAREPTA THERAPEUTICS, INC. Financials Nov 14 2014
Sarepta Initiates Dosing for Study Evaluating Eteplirsen Nov 13 2014
A Day Of Reckoning Approaches For Merck And Its Critics Nov 13 2014
Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients... Nov 12 2014
Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients... Nov 12 2014
INVESTOR ALERT: Investigation of Sarepta Therapeutics, Inc. Announced by Glancy Binkow & Goldberg... Nov 11 2014
Sarepta Therapeutics Announces Third Quarter 2014 Financial Results and Recent Corporate... Nov 11 2014
SHAREHOLDER ALERT: Investigation on Behalf of Sarepta Therapeutics, Inc. Investors Announced by Law... Nov 10 2014
Sarepta Q3 Loss Narrower-Than-Expected, Eteplirsen in Focus Nov 10 2014
10-Q for Sarepta Therapeutics, Inc. Nov 09 2014
Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today Nov 06 2014
Sarepta Therapeutics tops 3Q profit forecasts Nov 06 2014
Sarepta Therapeutics tops 3Q profit forecasts Nov 06 2014
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 06 2014
Q3 2014 Sarepta Therapeutics Inc Earnings Release - Before Market Open Nov 06 2014
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Nov 04 2014
Sarepta Therapeutics to Announce Third Quarter 2014 Financial Results and Corporate Update on... Oct 31 2014
Sarepta tumbles on new delay for key drug Oct 27 2014
Sarepta Therapeutics Announces Regulatory Update on Eteplirsen Oct 27 2014
Ahead of the Bell: Sarepta Therapeutics climbs Oct 17 2014
Sarepta Therapeutics Announces Publication of Ebola and Marburg Phase I Clinical Study Results in... Oct 16 2014
FDA sets approval path for Prosensa muscle disorder drug Jun 03 2014
Sarepta jumps on progress for muscle disorder drug Apr 21 2014
MARKET PULSE-AMD, Cbeyond, Halliburton, Plug Power, Prosensa, Sarepta Apr 21 2014
MARKET PULSE-AMD, Halliburton, Hasbro, Prosensa, Sarepta, Shanda Apr 21 2014
Sarepta Therapeutics to Present Company Overview at the 2014 Needham Healthcare Conference Mar 26 2014
Sarepta Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Recent... Feb 27 2014
Sarepta Therapeutics to Present Company Overview at the Cowen and Company 34th Annual Healthcare... Feb 20 2014
Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug... Feb 10 2014
Sarepta Therapeutics Announces Eteplirsen Demonstrates Stability on Pulmonary Function Tests through... Feb 05 2014
EU panel recommends against PTC Therapeutics drug Jan 24 2014
MARKET PULSE-Best Buy, Citi, Prosensa, Sarepta, Rentrak, Alamos Gold Jan 16 2014
Sarepta climbs on new data for muscle drug Jan 16 2014
Sarepta shares jump after hours on study results Jan 15 2014
Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test through... Jan 15 2014
Sarepta Therapeutics Names Art Krieg, M.D., Chief Scientific Officer Jan 09 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK